Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_sessionpdek7pt30m1r1ggg8hohhnub5ctgtijm): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
62 results match your criteria: ""Bianchi-Melacrino-Morelli" Great Metropolitan Hospital[Affiliation]"
Int J Mol Sci
October 2024
UOSD Medical Genetics, Great Metropolitan Hospital, 89124 Reggio Calabria, Italy.
The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong disease-free survival (DFS). Our phase III study compared the efficacy and safety of azacitidine (AZA) to best supportive care (BSC) in elderly AML patients who achieved CR following intensive induction and consolidation therapy. This ancillary study (QOL-ONE Trans-2) evaluated biological changes in bone marrow using Next-Generation Sequencing (NGS).
View Article and Find Full Text PDFDermatol Pract Concept
October 2024
Dermatology Unit, University of Campania "L. Vanvitelli".
Introduction: Tildrakizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin 23 (IL-23), has shown promise in the management of moderate-to-severe plaque psoriasis, offering potential improvements in clinical outcomes and quality of life.
Objectives: The study aimed to identify patient characteristics that indicate the initiation of a 200 mg dosage of tildrakizumab in a real-world setting, focusing on factors that enhance treatment effectiveness and safety.
Methods: This prospective study included 54 adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumab 200 mg from March 2023 to March 2024 across 13 Italian Dermatology Units.
Neurology
November 2024
From the Department of Medical and Surgical Sciences (A.P., S.G., U.A., E.F.), Magna Graecia University of Catanzaro; Regional Epilepsy Centre (A.P., S.G., U.A., E.F.), Unit of Pediatrics (D.S., D.M.), Unit of Medical Genetics (C.M.), and Unit of Neurology (V.C., C.P.), "Bianchi-Melacrino-Morelli" Great Metropolitan Hospital, Reggio Calabria, Italy.
Anaerobe
December 2024
Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, 34127, Trieste, Italy. Electronic address:
Epilepsia
October 2024
Department of Human Neurosciences, Sapienza University, Rome, Italy.
Antibiotics (Basel)
June 2024
Clinical Department of Medical, Surgical and Health Sciences, Trieste University, 34129 Trieste, Italy.
Infections caused by KPC-producing continue to pose a significant clinical challenge due to their emerging resistance to new antimicrobials. We investigated the association between two drugs whose roles have been repurposed against multidrug-resistant bacteria: fosfomycin and temocillin. Temocillin exhibits unusual stability against KPC enzymes, while fosfomycin acts as a potent "synergizer".
View Article and Find Full Text PDFJ Peripher Nerv Syst
June 2024
IRCCS Ospedale Policlinico San Martino, UOC Medical Genetics, Genoa, Italy.
Aim: Biallelic mutations in the PTRH2 gene have been associated with infantile multisystem neurological, endocrine, and pancreatic disease (IMNEPD), a rare autosomal recessive disorder of variable expressivity characterized by global developmental delay, intellectual disability or borderline IQ level, sensorineural hearing loss, ataxia, and pancreatic insufficiency. Various additional features may be included, such as peripheral neuropathy, facial dysmorphism, hypothyroidism, hepatic fibrosis, postnatal microcephaly, cerebellar atrophy, and epilepsy. Here, we report the first Italian family presenting only predominant neurological features.
View Article and Find Full Text PDFInfez Med
June 2024
Clinical Microbiology and Virology Unit, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
Hematol Oncol
July 2024
Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Neurology
May 2024
From the Department of Human Neurosciences (E.C.I., A.M., C.C., P. Pulitano, C. Panzini, A.T.G., C.D.B.), Sapienza University, Rome, Italy; Department of Precision Medicine and Genomics (E.C.), Department of Medicine, Columbia University, New York, NY; Department of Neurology (J.G., C.P.B.), Odense University Hospital; Department of Clinical Research (J.G., C.P.B.), University of Southern Denmark, Odense, Denmark; Department of Neurology (R.H.C.), Hospital de Pediatría "Prof. Dr. Juan P Garrahan," Buenos Aires, Argentina; Neurological Clinic (S.L.), Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona; Neurology Unit (G.S.), Department of Translational Medicine, University of Piemonte Orientale, and Azienda Ospedaliero-Universitaria "Maggiore della Carità," Novara; Neuromuscular and Sense Organs Department (E.R.), Careggi University Hospital, Florence; Regional Epilepsy Centre (E.F.), "Bianchi-Melacrino-Morelli" Great Metropolitan Hospital, Reggio Calabria; Department of Medical and Surgical Sciences, Magna Graecia University of Catanzaro; IRCCS NEUROMED (S.C., G.D.G.), Pozzilli, Isernia; Neurology Unit (C. Pizzanelli), Department of Clinical and Experimental Medicine, University of Pisa; Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia (L.G.)," Section of Neurosciences, University of Catania; IRCCS Istituto delle Scienze Neurologiche di Bologna (V.V., B.M.); Full member of the ERN EpiCARE; DIBINEM (V.V.), University of Bologna; Humanitas Gradenigo Hospital (P. Pignatta), Turin; Institute of Neurology (F.F., A.G.), University Magna Graecia, Catanzaro, Italy; Istanbul University Istanbul Faculty of Medicine (A.Ç.A., B.B.B.), Department of Neurology, Turkey; Neurophysiopatology and Movement Disorders Clinic (A.L.), University of Messina; Department of Science of Health School of Medicine (F.F.O.), University of Catanzaro, Italy; and EMAR Medical Center (B.B.B.), Istanbul, Turkey.
Eur J Clin Microbiol Infect Dis
May 2024
Microbiology and Virology Unit, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
Mult Scler
May 2024
Department of NEUROFARBA, University of Florence, Florence, Italy.
Clin Microbiol Rev
June 2024
Clinical Department of Medical, Surgical and Health Sciences, Trieste University, Trieste, Italy.
SUMMARY infection (CDI) is one of the major issues in nosocomial infections. This bacterium is constantly evolving and poses complex challenges for clinicians, often encountered in real-life scenarios. In the face of CDI, we are increasingly equipped with new therapeutic strategies, such as monoclonal antibodies and live biotherapeutic products, which need to be thoroughly understood to fully harness their benefits.
View Article and Find Full Text PDFEpilepsia
March 2024
Department of Human Neurosciences, Sapienza University, Rome, Italy.
Regulatory agencies have recently discouraged the prescription of topiramate (TPM) to women of childbearing potential with epilepsy due to growing evidence of the teratogenic and neurodevelopmental risks associated with its use during pregnancy. It remains, however, unclear whether the use of TPM in this population can be supported to some extent by its high effectiveness. In this multicenter, retrospective, cohort study performed at 22 epilepsy centers, we investigated the comparative effectiveness of TPM and levetiracetam (LEV) given as first-line antiseizure medication in a cohort of women of childbearing potential with idiopathic generalized epilepsy (IGE).
View Article and Find Full Text PDFAntibiotics (Basel)
November 2023
Infectious Diseases Unit, ARNAS Civico-Di Cristina Hospital, 90127 Palermo, Italy.
Human infections have high morbidity and mortality rates. bacteria can cause sepsis or septic shock; they produce biofilm and commonly exhibit a multidrug-resistant phenotype. The choice of antimicrobial therapy in many cases is challenging, and deep knowledge of clinical, microbiological, and pharmacological issues is required.
View Article and Find Full Text PDFEpilepsia
March 2024
Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
Epilepsia
February 2024
Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Objective: There are few comparative data on the third-generation antiseizure medications (ASMs). We aimed to assess and compare the effectiveness of brivaracetam (BRV), eslicarbazepine acetate (ESL), lacosamide (LCM), and perampanel (PER) in people with epilepsy (PWE). Efficacy and tolerability were compared as secondary objectives.
View Article and Find Full Text PDFOrphanet J Rare Dis
October 2023
Regional Coordinating Center for Rare Diseases, Udine University Hospital, Udine, 33100, Italy.
Infection
February 2024
Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, University "Magna Graecia", 88100, Catanzaro, Italy.
JAMA Neurol
November 2023
Department of Human Neurosciences, Sapienza University, Rome, Italy.
Importance: After the recent limitations to prescribing valproate, many studies have highlighted the challenging management of female patients of reproductive age with idiopathic generalized epilepsy (IGE). However, no study, to the authors' knowledge, has addressed the comparative effectiveness of alternative antiseizure medications (ASMs) in these patients.
Objective: To compare the effectiveness and safety of levetiracetam and lamotrigine as initial monotherapy in female patients of childbearing age with IGE.
Pharmaceuticals (Basel)
September 2023
Microbiology and Virology Unit, Great Metropolitan Hospital "Bianchi-Melacrino-Morelli", 89100 Reggio Calabria, Italy.
Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin.
View Article and Find Full Text PDFHaematologica
January 2024
Hematology Section, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari 'Aldo Moro', Bari.
Mycopathologia
August 2023
Clinical Pathology and Microbiology Unit, "S. Giovanni di Dio" Hospital, 88900, Crotone, Italy.
Endemic systemic mycoses such as blastomycosis, coccidioidomycosis, histoplasmosis, talaromycosis, paracoccidioidomycosis are emerging as an important cause of morbidity and mortality worldwide. We conducted a systematic review on endemic systemic mycoses reported in Italy from 1914 to nowadays. We found out: 105 cases of histoplasmosis, 15 of paracoccidioidomycosis, 10 of coccidioidomycosis, 10 of blastomycosis and 3 of talaromycosis.
View Article and Find Full Text PDFJ Clin Med
April 2023
Department of Cardiothoracic Surgery, Cardiovascular Research Institute, Maastricht University, 6211 LK Maastrich, The Netherlands.
Herein, we describe a 54-year-old patient with a congenital ventricular diverticulum (CVD), referred to our emergency department for presyncope episodes and multiple re-entrant ventricular tachycardias (VT). Significantly, echocardiographic findings were not clear, and the diagnosis was made by cardiac magnetic resonance imaging (CMRI), which showed the presence of an apical accessory cavity connected to the ventricle and contracting synchronously. CMRI allowed the differential diagnosis with other outpouching cardiac defects.
View Article and Find Full Text PDFCancers (Basel)
April 2023
Divisione di Ematologia, Ospedale Belcolle, 01100 Viterbo, Italy.
This phase-3 randomized multicenter trial evaluated the efficacy of subcutaneous azacitidine (AZA) post-remission therapy vs. best supportive care (BSC) in elderly acute myeloid leukemia (AML) patients. The primary endpoint was the difference in disease-free survival (DFS) from complete remission (CR) to relapse/death.
View Article and Find Full Text PDF